Long Term Safety Study of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Amifampridine (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions
- Acronyms SMA3
- Sponsors Catalyst Pharmaceuticals
Most Recent Events
- 14 Mar 2022 Status changed from recruiting to discontinued.
- 20 Aug 2021 This trial is has been discontinued, according to European Clinical Trials Database record.
- 14 Feb 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.